Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H.
Haddad FG, et al.
Am J Hematol. 2023 Oct;98(10):1619-1626. doi: 10.1002/ajh.27037. Epub 2023 Jul 23.
Am J Hematol. 2023.
PMID: 37485584
In summary, patients with CML-CP at the time of T315I mutation detection may have a relatively indolent disease course with a long-term OS of 70%. Treatment with third-generation tyrosine kinase inhibitors seemed to improve survival in patients with CML-CP....
In summary, patients with CML-CP at the time of T315I mutation detection may have a relatively indolent disease course with a long-term …